statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Biodexa Pharmaceuticals Unveils Series J Warrant

Biodexa Pharmaceuticals (BDRX) has released an update. Biodexa Pharmaceuticals has announced a new Series J Warrant to purchase ordinary shares, ex...

Cancer-Focused Nano-Cap Biodexa Pharmaceuticals Stock Is Surging On Thursday - Here's Why

Biodexa Pharmaceuticals shares surge following phase 2 trial results for eRapa, a potential treatment for Familial Adenomatous Polyposis. The study showed a 17% median reduction in polyp burden and a...

Biodexa Pharma Announces Executive Departure

Biodexa Pharmaceuticals (BDRX) has released an update. Biodexa Pharmaceuticals PLC has announced the departure of Dmitry Zamoryakhin, its Chief Sci...

Biodexa Pharmaceuticals Stock Is Tumbling Wednesday: What's Going On?

Biodexa announced the exercise of previously issued warrants and an agreement between the company and several investors to exercise certain existing Series E and Series F warrants to purchase up to...

Biodexa's MTX110 Shows Promise In Extending Life Expectancy Against Aggressive Brain Cancers

Topline Results For Progression-Free Survival Expected In Q2 2024CARDIFF, UK / ACCESSWIRE / March 28, 2024 / Biodexa Pharmaceuticals (NASDAQ:BDRX) ('Biodexa'), an acquisition-focused...

Extend Life Expectancy Against Aggressive Brain Cancers - Nano-Cap Firm Biodexa's Investigational Drug Shows Potential

Biodexa Pharmaceuticals' MTX110, revolutionizing brain cancer treatment with innovative drug delivery technology. Early trials show promising survival rate extensions in Diffuse Midline Glioma and...

Why Is Biodexa Pharmaceuticals (BDRX) Stock Up 106% Today?

InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Biodexa Pharmaceuticals stock is up alongside heavy trading of BDRX after announcing positive news from a brain cancer treatment...

Biodexa Takes Aim At Type 1 Diabetes With Innovative Drug Candidate Tolimidone

Orally dosed small molecule candidate is designed to reduce/eliminate need for injectable insulinTopline data from Phase 2a program expected by year-endSafety profile established in more than 700...

Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update

Biodexa Pharmaceuticals PLC( Biodexa or the Company ) Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update Median Overall...

12 acciones de salud en movimiento en la subasta de cierre del 12/02/2024

Acciones al alza
Biodexa Pharmaceuticals (NASDAQ:BDRX) se anotaron un alza del 14,48% para establecerse en los 1,66 d lares durante la sesi n del after-market del lunes.
China Pharma Holding...

Biodexa Pharmaceuticals Plc is a drug delivery technology company. It is focused on the research and development of medicines for rare cancers, via both in-house programs as well as partnered programs. The firm's proprietary platform drug delivery technologies are Q-Sphera platform is a disruptive polymer microsphere technology, which is used for sustained release at the microscale to prolong and control the release of therapeutics over an extended period of time from weeks to months; Midasolve platform is an innovative nano saccharide technology, which is used to dissolve drugs at the nanoscale so that they can be administered in liquid form directly and locally into tumors; Midacore platform is an edge gold nanoparticle technology, which is used for targeting sites of disease at the nanoscale. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

Volume	272,208.00
52-Wk High	$9.64
52-Wk Low	$0.67

BDRX Biodexa Pharmaceuticals Plc

About

Feed

News

Sentiment

Fundamentals